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ABSTRACT

DISSECTING THE MECHANISMS OF VENETOCLAX RESISTANCE IN MYELODYSPLASTIC
SYNDROMES
Shuaitong Chen, B.A.
Advisor: Simona Colla, Ph.D.
Myelodysplastic syndromes (MDS) are a class of heterogeneous clonal hematopoietic
disorders. The current standard of care for MDS is the hypomethylating agent (HMA)-based
therapy. However, only 50 percent of the patients respond, with transient effects and no
approved second-line treatment options after their diseases progress to acute myeloid
leukemia (AML). The mechanisms that govern HMA failure are unknown. Recently, we
unveiled that MDS are maintained and propagated by two different immunophenotypically
distinct hierarchical cellular organizations of MDS hematopoietic stem and progenitor cells
(HSPCs) through the upregulation of specific survival pathways. This finding allowed us to
potentially stratify MDS patients into two subgroups for more effective guided therapy choices.
Herein, we provide evidence that one of the two subgroups of MDS patients can
achieve a more favorable clinical response to BCL2 inhibition by venetoclax-based therapy.
Our preliminary data reveal that MCL1 is one of the determinants of venetoclax resistance in
MDS patients and that combining MCL1 inhibition and venetoclax can synergistically eradicate
venetoclax-resistant MDS blasts and HSPCs in vitro and reduce tumor burden in patientderived xenografts. Additionally, in patients enrolled in clinical trials of venetoclax, we observed
an expansion of a subset of CD4+ T cells with naïve and/or early-activated antigen-experienced
phenotype only when the patients responded to venetoclax-based therapy, indicating a
possible role of the adaptive immune system in mediating venetoclax response. This study
substantiates the reliability of MDS patient stratification based on their immunophenotype in the
clinical use of venetoclax-based therapy and assesses the feasibility of targeting MCL1 in
venetoclax-resistant MDS patients as a novel therapeutic option to improve their survival.
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CHAPTER 1: INTRODUCTION
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1.1 Myelodysplastic Syndromes (MDS) and the Hematopoietic Hierarchy

1.1.1 Overview
Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic
disorders characterized by ineffective and dysplastic hematopoiesis [1]. Clinically, MDS
patients display symptoms such as peripheral blood cytopenia, bone marrow hyperplasia,
dysplasia, and a high risk of progression to acute myeloid leukemia [2]. In recent years, a
dramatic increase in MDS incidence due to the aging of the population and increased cases of
therapy-related MDS in cancer survivors has emphasized the importance of developing
therapies to improve the survival of MDS patients [3].

1.1.2 The Hematopoietic Hierarchy
The key to understanding the pathology and progression of MDS is to investigate the
mechanisms that regulate hematopoiesis and its functional dynamics. Hematopoiesis is a
process that gives rise to all types of blood cells, which is governed by hematopoietic stem
cells (HSCs) that reside in the bone marrow and possess the ability of self-renewal and
differentiating into downstream progenitor cells [4]. The hierarchy of hematopoiesis was initially
defined as the differentiation of HSCs as a discrete process based on early studies in mice [5,
6]. As the investigation of hematopoiesis has incorporated high-throughput single-cell
transcriptomic analyses, the hierarchy of hematopoiesis has been supplemented with the
identification of new HSC populations and the expansion of the complexity of lineage
differentiation [7]. More importantly, these single-cell technologies have led to the current
interpretation of hematopoietic hierarchy as a continuum process in which lineage specification
is defined by the cells’ transcriptional state, which mostly depends on transcription factor
dynamics [8].
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In humans, the long-term hematopoietic stem cells (LT-HSCs), which reside at the top
of the hierarchy in the HSC compartment, represent a very rare population among cells in the
bone marrow and proliferate mostly under conditions of stress [9]. They produce multipotent
progenitors (MPPs), which frequently undergo differentiation into myeloid-biased common
myeloid progenitors (CMPs), and lymphoid-biased lymphoid-primed multipotent progenitors
(LMPPs). CMPs then differentiate into megakaryocyte/erythrocyte progenitors (MEPs) and
granulocyte/monocyte progenitors (GMPs), while LMPPs give rise to common lymphoid
progenitors (CLPs) (Figure 1) [9]. The progenitor cells further differentiate into more committed
downstream blood cells that enter circulation in the body bearing distinct functions [9].

Figure 1. Human adult hematopoiesis
HSCs reside in the bone marrow and possess lifelong self-renewal and differentiation potential.
Within the Lin-CD34+CD38- HSC compartment, there are long-term hematopoietic stem cells
(LT-HSCs), multipotent progenitors (MPPs), and lymphoid-primed multipotent progenitors
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(LMPPs). Cells in the HSC compartment give rise to downstream progenitor populations,
including megakaryocyte/erythrocyte progenitors (MEPs), common myeloid progenitors
(CMPs), granulocyte/monocyte progenitors (GMPs), and common lymphoid progenitors
(CLPs). CMPs are able to generate MEPs and GMPs for further maturation and differentiation
of the myeloid lineages; MEPs further generates megakaryocytes and erythrocytes; GMPs
differentiate into granulocytes, monocytes, and dendritic cells. CLPs mostly give rise to the
lymphoid lineages, including T cells, natural killer (NK) cells, and B cells.

1.1.3 Clonal Hematopoiesis and Genetics of MDS
During aging, HSCs can acquire cumulative genetic alterations such as chromosomal
aberrations and/or somatic mutations that confer survival advantages to the mutant cells over
their normal counterparts [10-13]. Initially, these mutations can start by affecting only small
populations of bone marrow cells, a process known as clonal hematopoiesis of indeterminate
potential (CHIP). Over time, once additional disease-driving mutations occur, or under pressure
from other external factors such as inflammation or chemotherapy [14], these CHIP clones can
expand and evolve into MDS. MDS can then eventually progress to AML, mostly after therapy
failure, when MDS clones acquire secondary mutations or undergo clonal evolution [11, 14-16].
Figure 2 summarizes the initiation and progression of MDS [17].
In the past two decades, the application of advanced genomic technologies has
dramatically improved our understanding of the driver mutations associated with the positive
selection of MDS clones. Early studies on the genetics of MDS focusing on cytogenetic
abnormalities have revealed that about 50% of MDS patients have chromosomal and copynumber abnormalities (CNAs), of which the most frequent are -7 or del(7q) and -5 or del(5q)
[18]. Additionally, recurrent somatic mutations in various functional pathways such as DNA
methylation, chromatin/histone modification, splicing, and transcription have been identified in
MDS [19, 20]. Mutations in genes that regulate epigenetic programs are the most frequently
4

observed, including mutations in TET2, DNMT3A, and IDH1/2, involved in DNA methylation;
ASXL1, MLL2, and EZH2, involved in chromatin/histone modification; and SF3B1, SRSF2, and
U2AF1, involved in RNA splicing regulation [21]. These mutant proteins play essential roles in
hematopoiesis as they regulate the expression of genes that are fundamental for HSC selfrenewal and differentiation [22].

Figure 2. Schematic of clonal hematopoiesis and propagation of hematologic
malignancies.
Early mutations (indicated as red circles) in hematopoietic stem cells (HSCs) initiate clonal
hematopoiesis of indeterminate potential (CHIP). As HSCs acquire more disease-driving
mutations (indicated as blue and orange circles), CHIP can progress to myelodysplastic
syndromes (MDS) and eventually acute myeloid leukemia (AML). The figure is adapted from
Steensma et al. Blood 2015 [17].

5

1.2 The Standard of Care for MDS
The current standard of care for MDS patients is hypomethylating agent (HMA)-based
therapy using 5'-azacitidine or decitabine, which partially restores functional hematopoiesis,
improves overall survival, and delays progression to AML compared to conventional therapy
[23, 24]. The exact mechanisms and molecular targets of HMAs in MDS are unclear. Since
anomalous epigenetic regulation is one of the consequences of recurrent somatic mutations in
MDS, tumor suppressor genes that are crucial in regulating DNA damage, differentiation, and
transcription might be silenced due to DNA hypermethylation mediated by DNA methyltransferases
(DMNTs) [25]. 5-azacytidine and decitabine are examples of clinically effective HMAs that work
by incorporating into DNA to target DNMTs for degradation, potentially inducing DNA
hypomethylation and restoring gene transcription [26, 27]. However, the precise mechanisms
involved in the direct association of DMNT inhibition and induction of DNA hypomethylation
remain ambiguous [28].
In MDS, only 40-50% of the patients respond to HMA therapy with a transient response
of 6 to 24 months. HMA treatment failure is usually followed by a poor prognosis and disease
progression [29]. The only curative treatment for MDS is stem cell transplantation (SCT).
However, not all MDS patients are eligible because of age and comorbidities [30]. Thus, MDS
patients with HMA failure who are not eligible for SCT are in urgent need of effective secondline treatment options to improve their outcomes.

1.2 Novel Stratification of MDS and its Clinical Implications

1.3.1 “CMP Pattern” and “GMP Pattern” MDS
In order to provide MDS patients with more effective, precise, and personalized
treatment, researchers have put enormous effort on elucidating a precise stratification of MDS
patients over time. The gold standard for clinical risk assessment in MDS patients are the
6

International Prognostic Scoring System (IPSS) and Revised International Prognostic Scoring
System (IPSS-R) that classify patients based on their blast count and the number of
cytogenetic abnormalities and cytopenias [31]. However, although there have been significant
refinements of the stratification and prognostication of MDS patients, both the IPSS and IPSSR are limited to a particular group of patients and lack a base in molecular pathology [32].
Our lab has previously demonstrated that MDS patients can be stratified into two
immunophenotypically and biologically distinct entities based on the bone marrow (BM) HSPC
hierarchy. Specifically, we characterized the immunophenotypic profile of the HSPC
compartment in a cohort of 123 BM samples isolated from untreated MDS patients.
Unsupervised hierarchical clustering based on the frequency of immunophenotypically defined
HSPC populations followed by principal component analysis stratified the MDS samples into
two main groups. Compared with BM samples from age-matched healthy donors, the BM
samples of one of the MDS groups (52% of the samples) had an abnormal differentiation
pattern characterized by an increased frequency of CMPs within the myeloid hematopoietic
progenitor cell (MyHPC) compartment (a “CMP pattern” of differentiation) owing to significantly
decreased frequencies of GMPs and MEPs in the total BM mononuclear cells (MNCs). In
contrast, the BM samples of the other MDS group (48% of the samples) had a higher frequency
of GMPs within the MyHPC compartment (a “GMP pattern” of differentiation) owing to
significantly decreased frequencies of CMPs and MEPs in the total BM MNCs. These 2
different MDS patterns were associated with distinct mutational landscapes that accounted for
these subtypes’ different HSPC hierarchies. Specifically, we found that mutations in RUNX1,
BCOR, STAG2, and DNMT3A were significantly more prevalent in “GMP pattern” MDS,
whereas mutations in TP53 and U2AF1 were associated with the “CMP pattern” phenotype.
The immunophenotypic compositions of the 2 MDS subgroups’ upstream HSC
precursors were significantly different. Specifically, whereas “CMP pattern” MDS samples had
higher frequencies of LT-HSCs and MPPs, “GMP pattern” MDS samples had a significantly
7

higher frequency of LMPPs. These distinct HSC architectures arose from a significant
expansion of the LMPPs in “GMP pattern” MDS in the context of an overall decrease in the
frequencies of LT-HSCs and MPPs in total BM MNCs (Figure 3).
1.3.2 Progression of MDS is Associated with the Immunophenotypically-defined HSPC
Hierarchy
In our study we also sought to elucidate the biological mechanisms underpinning blast
progression (BP) in the two MDS groups, as such an understanding might lead to the
development of new therapeutic approaches to prevent or overcome HMA failure. Given that
HMA failure is mostly independent of the molecular and genetic alterations in the founder clone
[33] and that BP is mostly associated with the expansion of HSC clones carrying preexisting or
newly acquired recurrent mutations in genes involved in signal transduction and transcriptional
and epigenetic regulation [16, 34, 35], we hypothesized that HSC expansion can be induced by
key oncogenic pathways that are recurrently activated in each MDS group. To test this
hypothesis, we evaluated gene expression changes in LT-HSC and LMPP populations isolated
from “CMP pattern” and “GMP pattern” MDS patients, respectively, whose disease had become
resistant to HMA therapy and progressed to higher-risk disease or AML.
RNA-seq analysis revealed that, compared with those isolated from untreated patients,
LT-HSCs isolated from “CMP pattern” MDS patients with BP following HMA therapy failure had
significantly upregulated genes involved in promoting cell proliferation and survival, including
the anti-apoptotic regulator B-cell lymphoma 2 (BCL2). In striking contrast to our findings in
“CMP pattern” MDS, genes involved in the tumor necrosis factor alpha (TNF)-induced nuclear
factor-kappa B (NF-B) signaling pathway were significantly upregulated in the LMPPs from
“GMP pattern” MDS patients with BP as compared with LMPPs from “GMP pattern” MDS
patients with newly diagnosed disease. These results have led to the hypothesis that “CMP
pattern” MDS patients with BP may benefit from BCL2 inhibition and “GMP pattern” patients
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with BP may benefit from NF-B inhibition. Indeed, our most exciting finding was that the
pharmacological inhibition of either of these pathways selectively depletes the respective MDS
stem cell types in vitro and decreases tumor burden in patient-derived xenograft models. On
the basis of these results, we hypothesized that targeting BCL2 with venetoclax elicits a
durable response in “CMP pattern” MDS, potentially providing a means of improving patient
stratification in clinical trials of this drug. These results have led to clinical trials of venetoclaxbased therapy in MDS patients following HMA failure at MD Anderson Cancer Center.
In this Thesis, I sought to understand the mechanisms that contribute to venetoclax
response and resistance by analyzing sequential BM samples isolated from MDS patients
enrolled in prospective clinical trials and identify novel therapeutic targets that can overcome
venetoclax resistance in order to improve the survival and prognosis of MDS patients
effectively. Given that the upregulation of myeloid cell leukemia 1 (MCL1) is one of the
mechanisms of resistance to venetoclax identified among AML patients and can be
upregulated downstream by NF-B [36, 37], we hypothesized that MCL1 inhibition, alone or in
combination with venetoclax, can effectively target MDS at progression in patients who failed
HMA therapy alone or in combination with venetoclax. Indeed, recent pre-clinical studies in
chronic lymphocytic leukemia (CLL) and AML have shown the synergistic effect of BCL2 and
MCL1 inhibition in suppressing the growth of blasts and leukemogenic stem cells [38-40].
However, whether this combination will have an effect in MDS has not been elucidated.

9

Figure 3. MDS are maintained by distinct and recurrent cellular hierarchies.
Previous findings by Ganan-Gomez et al. demonstrated that MDS patients can be stratified into
two immunophenotypically and biologically distinct entities based on the hematopoietic stem
and progenitor cell (HSPC) hierarchy. Long-term hematopoietic stem cells (LT-HSCs) rely on
BCL2 upregulation for survival and drive disease progression in the “CMP pattern” MDS.
Lymphoid-primed multipotent progenitors (LMPPs) upregulate NF-B signaling pathways for
survival and drive disease progression in the “GMP pattern” MDS. Figure taken from GananGomez et al. (under revision in Nature).
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1.3 Apoptosis and BCL2 Family Proteins

1.4.1 BCL2 Family Proteins Mediate the Intrinsic Apoptosis Pathway
To maintain homeostasis, human bodies require programmed cell death to remove
damaged or dysfunctional cells that disrupt normal physiology and tissue functions. Apoptosis
is one of the conserved and regulated mechanisms of programmed cell death orchestrated by
both extrinsic and intrinsic signaling pathways [41]. Composed of both pro-survival and proapoptotic members, BCL2 family proteins mediate the intrinsic apoptosis pathway by triggering
mitochondrial outer membrane permeabilization (MOMP). Following MOMP, the subsequent
release of cytochrome c from the mitochondria is activated by pro-apoptotic BCL2 family
members (BAX, BAK1, BIM, BID, and PUMA), which can be antagonized by the anti-apoptotic
BCL2 family members (BCL2, BCL-XL, BCL-W, BCL2-A1, and MCL1). Each member in this
family has at least one of the four BCL2 homology (BH) domains (BH1-BH4). The pro-apoptotic
family members are the BH3-only proteins (BIM, BID, NOXA, BIK, PUMA, BMF, and HRK)
which, as the name indicates, contain only the BH3 domain. They bind to anti-apoptotic
members and consequently unleash BAX/BAK and initiate apoptosis through MOMP. As a
result, cytochrome c is released into the cytoplasm, leading to the formation of apoptosome
and downstream caspase signaling activation [42-44].

1.4.2 Targeting Anti-apoptotic Mechanisms with BH3 Mimetics
Resistance to cell death is one of the hallmarks of cancer [45]. One of the mechanisms
contributing to the evasion of apoptosis in cancer cells is the upregulation of the expression of
pro-survival members of the BCL2 protein family. Indeed, the overexpressed pro-survival
members sequester the pro-apoptotic members, preventing them from activating MOMP [43].
The identification of this anti-apoptotic mechanism in multiple cancer types, along with insightful
studies on the structural interactions between pro-survival and pro-apoptotic members, has led
11

to the development of small molecule drugs called “BH3 mimetics” that are designed to mimic
the binding of BH3-only BCL2 family members to pro-survival members. Since BH3 mimetics
are engineered to have a much higher binding affinity to the pro-survival BCL2 family proteins
than the actual BH3-only proteins, they are capable of disrupting protein-protein interactions
between BH3-only proteins and pro-survival proteins, such that the BH3-only proteins are set
free to initiate apoptosis [46].

1.4.3 Venetoclax (ABT-199) and AMG-176
Re-engineered from navitoclax (ABT-263), which was the first orally available BH3
mimetic, venetoclax (ABT-199) is a selective BCL2 inhibitor. First reported in 2013 [47],
venetoclax has demonstrated great anti-neoplastic effectiveness as a single agent or in
combination with approved cancer therapies in preclinical/clinical studies for various cancer
types, leading to the FDA approval of venetoclax in combination with other therapies as a
treatment for CLL patients with 17p deletion in 2016 [48] and for newly-diagnosed AML patients
in 2018 [49]. Unlike navitoclax, ABT-199 had less binding affinity to BCL-XL, which is critical for
platelet survival in order to prevent thrombocytopenia [47].
Although venetoclax treatment has greatly improved the survival of patients with
hematologic malignancies, primary or secondary resistance to venetoclax can eventually occur.
MCL1 is one of the pro-survival members of BCL2 family proteins whose upregulation has
been identified as one of the mechanisms of venetoclax resistance [50-52]. These findings
have led to the development of the BH3 mimetics S63845, S64315/MIK665, AMG176 and
AZD5991, each targeting MCL1 activity [40, 53, 54]. AMG-176 was first reported by Caenepeel
et al. in 2018 as a novel orally bioavailable MCL1 inhibitor that could induce tumor cell
apoptosis in multiple myeloma xenografts and have significant synergistic effect on killing AML
cells in vivo in combination with venetoclax treatment [53]. Thus, in our pre-clinical study, we
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utilized AMG-176 to evaluate the efficiency of MCL1 inhibition, as monotherapy or in
combination with venetoclax, in overcoming venetoclax resistance.
Moreover, recent studies have linked venetoclax response to T lymphocyte activities in
which venetoclax could lead to an increase in intratumoral CD8+ memory T cells, potentially
enhancing the anti-tumor immune response when combined with immunotherapy [55]. Thus,
besides the direct targeting of venetoclax to BCL2-expressing cancer cells, venetoclax may
also induce an anti-tumor adaptive immune response by augmenting T lymphocytes'
cytotoxicity [56].

1.5 The Biology and Development of T Lymphocytes
Our immune system is composed of various immune cells that are responsible for
recognizing and fighting non-self pathogens. The engagement of the immune system in cancer
patients has become a central focus for understanding the complexity dynamics and
interactions among cancer cells, tumor microenvironment, and cancer therapeutics. The T
lymphocyte in particularly, with its capacity for antigen-directed cytotoxicity, exhibits a great
potential for application in cancer immunotherapy and vaccinology, and has led to extensive
study of its biology and development [57].
The progenitors of T cells originate in the BM and then migrate to the thymus and
initiate T cell development. Early committed T cells are termed “double-negative” T cells owing
to their lack of CD4 and CD8 T cell receptor (TCR) expression. Once they are able to
successfully express CD4 and CD8 pre-TCRs, they will transit to double-positive T cells and
further, depending on their binding ability and affinity to either MHC I complex or MHC II
complex during positive and negative selections, become single-positive (SP) T cells with the
expression of either CD4 or CD8 [58]. Within each SP subset, there are various T cell
subpopulations that have been identified with distinct functions. These include the following:
naïve T cells (TN, CD45RA+CD45RO-CD95-CCR7++), stem-cell-like memory T cells (TSCM,
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CD45RA+CD45RO-CD95+CCR7+), effector T cells (TE, CD45RA+CD45RO-CD95+CCR7-),
central memory T cells (TCM, CD45RA-CD45RO+CD95+CCR7+), effector memory T cells (TEM,
CD45RA-CD45RO+CD95+CCR7-), and regulatory T cells (Treg, CD4+CD25+FOXP3+CD127lo).
Following antigen recognition, naïve T cells become activated and develop the ability to
differentiate into multiple memory T cell subsets. TSCM is the subset that has come across
antigen; however, it maintains a naïve-like phenotype in which it is able to sustain its selfrenewal ability and reconstitute the full spectrum of memory and effector T cells [59]. More
committed memory T cells are composed of TCM and TEM, distinguished based on the presence
and absence of surface lymph node homing receptor CD62L (L-selectin) and C-C chemokine
receptor 7 (CCR7) [60]. The memory T cell subsets are the key to the sustainability of longterm immunity as they recognize and respond to the re-stimulation of previously exposed
antigens and differentiate into TE to launch cytotoxic activities [61, 62]. Lastly, Treg is an
immunosuppressive CD4+ T cell subset that maintains tolerance to self-antigens through the
downregulation of effector T cell activities to prevent autoimmune diseases [63].
T cell are key mediators in immune surveillance and anti-tumor activities. Recent
studies have reported significant population changes in T cells in response to venetoclax
treatment in cancer patients [55, 56]. In this Thesis, I also sought to understand whether T cellmediated immunity could potentially play a part in venetoclax response in MDS.
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
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Based on our previous studies, we hypothesized that “CMP pattern” MDS patients can
achieve favorable clinical outcomes in response to BCL2 inhibition by venetoclax-based
therapy. In addition, since MCL1 upregulation is a potential determinant of venetoclax
resistance in AML [52] and MCL1 is the downstream target of NF-B pathway activation [64],
we also hypothesized that MCL1 inhibition, alone or in combination with venetoclax can
effectively overcome venetoclax resistance in MDS.
To test our hypotheses, I pursued the following two specific aims:

Aim #1. Identify predictive biomarkers of venetoclax response and resistance by
analyzing sequential BM samples from MDS patients enrolled in prospective clinical
trials
1a. Test the hypothesis that venetoclax-based therapy can selectively eradicate “CMP
pattern” MDS HSCs.
To achieve this aim, I evaluated the correlation between the 2 MDS HSPC architectures
and the clinical response to veneclax-based therapy.
1b. Dissect molecular determinants of venetoclax response and resistance in different
cell types.
To achieve this aim, I performed scRNA-seq analysis of BM MNCs and Lin-CD34+
HSPCs from sequential BM samples isolated from patients enrolled in the venetoclax-based
clinical trials at different therapy time points (before therapy, and at the times of remission,
stable disease, and progression).
1c. Evaluate whether venetoclax response, resistance, or failure is associated with the
differential expression of key anti-apoptotic proteins.
To achieve this aim, I performed cytometry by time-of-flight (CyTOF) analysis of BM
MNCs isolated from sequential BM samples isolated from patients enrolled in the venetolaxbased clinical trials at different therapy time points (as defined in aim 1b).
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1d. Evaluate whether the adaptive immune system plays a role in mediating the
response to venetoclax-based therapy.
To achieve this aim, I evaluated whether venetoclax-based therapy induces
immunophenotypic changes in composition of the T and NK cell compartments.

Aim #2. Assess the feasibility of targeting MCL1 in patients with venetoclaxresistant MDS.
2a. Evaluate whether AMG-176 alone or in combination with venetoclax can eradicate
venetoclax-resistant blasts and HSPCs in vitro.
To achieve this aim, I treated the MDS cell line MDS-L and primary samples from
patients with MDS at the time of progression, in co-culture with mesenchymal cells, with AMG176 alone or in combination with venetoclax.
2b. Evaluate whether AMG-176 can eradicate venetoclax-resistant tumor burden in
vivo.
To achieve this aim, I treated patient-derived xenografts with AMG-176 alone or in
combination with venetoclax.
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CHAPTER 3: MATERIALS AND METHODS
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Human primary samples and cell lines. BM specimens from 35 patients who were diagnosed
with MDS or secondary AML and referred to the Department of Leukemia at MD Anderson
Cancer Center were obtained with the approval of the Institutional Review Board and in
accordance with the Declaration of Helsinki. Written informed consent was obtained from all
donors, and all MDS diagnoses were confirmed by dedicated hematopathologists. Responses
to therapy in patients enrolled in clinical trials were assessed by dedicated hematologists. BM
MNCs were isolated from each sample using the standard gradient separation approach with
Ficoll-Paque PLUS (GE Healthcare Lifesciences, Pittsburgh, PA). For cell sorting applications,
MNCs were enriched in CD34+ cells using magnetic sorting with the CD34 Microbead Kit
(Miltenyi Biotec, San Diego, CA) and further purified by flow cytometric sorting as described
below. For transplantation purposes, CD3+ cells were depleted from the BM MNCs by using
magnetic sorting with the CD3 Microbead Kit (Miltenyi Biotec, San Diego, CA). Human BMderived mesenchymal stromal cells (MSCs) were obtained from healthy BM donors as
previously described [65] and kindly provided by Dr. Michael Andreeff from the Department of
Leukemia at MD Anderson. The MDS-L cell line was kindly donated by Dr. Kaoru Tohyama
(Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan). The identity
of the MDS-L line was confirmed by short tandem repeat DNA fingerprinting at MD Anderson’s
Characterized Cell Line Core Facility.

Flow cytometry and fluorescence-activated cell sorting. Quantitative flow cytometric
analyses and fluorescence-activated cell sorting (FACS) of human live MNCs and CD34+ cells
were performed using previously described staining protocols [13, 66] and antibodies against
CD2 (RPA- 82.10), CD3 (SK7), CD14 (MφP9), CD19 (SJ25C1), CD20 (2H7), CD34 (581),
CD56 (B159), CD71 (M-A712), CD123 (9F5), and CD235a (HIR2; all from BD Biosciences);
CD4 (S3.5), CD11b (ICRF44), CD33 (P67.6), CD45RA (MEM-56), and CD90 (5E10; all from
Thermo Fisher Scientific); CD7 (6B7), CD38 (HIT2), and CD135 (6H6; all from BioLegend, San
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Diego, CA); and CD10 (SJ5-1B4; Leinco Technologies, St Louis, MO). Stem and progenitor cell
populations were classified using published definitions [67-69]. Detailed information about the
flow cytometry and FACS settings and the antibody panels used to identify specific HSPC
populations is provided in Table 1.
POPULATION
LIVE CELLS

GATING STRATEGY
Single cells/Sytox Green Nucleic Acid Stain negative
(Thermo Fisher Scientific)

LINEAGE NEGATIVE CELLS
(LIN-)
HSC COMPARTMENT

CD2-, CD3-, CD4-, CD7-, CD10-, CD11b-, CD14-,
CD19-, CD20-, CD33-, CD56-, CD235aLive/Lin-/CD34+, CD38-

LT-HSCs

Live/Lin-/CD34+, CD38-/CD90+, CD45RA-

MPPs

Live/Lin-/CD34+, CD38-/CD90-, CD45RA-

LMPPs

Live/Lin-/CD34+, CD38-/CD90-, CD45RA+

MyHPC COMPARTMENT

Live/Lin-/CD34+, CD38+

CMPs

Live/Lin-/CD34+, CD38+/CD123+, CD45RA-

GMPs

Live/Lin-/CD34+, CD38+/CD123+, CD45RA+

MEPs

Live/Lin-/CD34+, CD38+/CD123-, CD45RATable 1. Immunophenotypic HSPC definitions used in the quantification and purification
of human HSPCs by flow cytometry
Abbreviations: HSPC, hematopoietic stem and progenitor cell; HSC, hematopoietic stem cell;
LT-HSCs, long-term HSCs; MPPs, multipotent progenitors; LMPPs, lymphoid-primed MPPs;
MyHPC, myeloid hematopoietic progenitor cell; CMPs, common myeloid progenitors, GMPs,
granulocyte-monocyte progenitors; MEPs, megakaryocyte-erythroid progenitors.

In patient-derived xenograft mice, human chimerism was analyzed by staining the
mouse BM suspensions, prepared as described above, with antibodies against human CD45
(clone HI30) and mouse CD45 (clone 30-F11; both from BioLegend).
For immune cell analysis, BM MNCs were stained with antibodies against CD56
(5.1H11), CD16 (3G8), CD3 (UCHT1), CD4 (RPA-T4), CD8 (SK1), CD45RO (UCHL1),
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CD45RA (HI100), CD197 (G043H7), CD95 (DX2), CD25 (BC96), CD127 (A019D5), and
FOXP3 (206D; all from BioLegend). Detailed information about the flow cytometry and FACS
settings and the antigen panels used to identify specific immune cell populations is provided in
Table 2.
POPULATION GATING STRATEGY
LIVE CELLS

Single cells/ Zombie UV™ Fixable Viability negative (BioLegend)

NK CELLS
T CELLS

Live CD3-CD56+CD16hi/lo
Live CD3+CD56-CD4+ and Live CD3+CD56-CD8+

TN

Live/CD3+CD56-CD4+/CD45RA+CD45RO-CD95-CCR7++ and Live/
CD3+CD56-CD8+/CD45RA+CD45RO-CD95-CCR7++

TSCM

Live/CD3+CD56-CD4+/CD45RA+CD45RO-CD95+CCR7+ and Live/
CD3+CD56-CD8+/CD45RA+CD45RO-CD95+CCR7+

TCM

Live/CD3+CD56-CD4+/CD45RA-CD45RO+CD95+CCR7+ and Live/
CD3+CD56-CD8+/CD45RA-CD45RO+CD95+CCR7+

TEM

Live/CD3+CD56-CD4+/CD45RA-CD45RO+CD95+CCR7- and Live/
CD3+CD56-CD8+/CD45RA-CD45RO+CD95+CCR7-

TE

Live/CD3+CD56-CD4+/CD45RA+CD45RO-CD95+CCR7- and Live/
CD3+CD56-CD8+/CD45RA+CD45RO-CD95+CCR7-

Treg

Live/CD3+CD56-CD4+CD25+FOXP3+CD127lo
Table 2. Immune cell definitions used in the quantification of human NK cells and T cells
by flow cytometry
Abbreviations: NK, natural killer; TN, naïve T cells; TSCM, stem cell memory T cells; TCM, central
memory T cells; TEM, effector memory T cells; TE, terminal effector T cells; Treg: regulatory T
cells.

For Annexin V/DAPI apoptosis analysis, MDS-L cells were incubated with fluorochromeconjugated Annexin V (Miltenyi Biotec, San Diego, CA) in 1X binding buffer for 10-15 minutes
at RT in the dark. Then cells were washed with binding buffer and resuspended in 4',6Diamidino-2-Phenylindole, Dihydrochloride (DAPI) solution.
Samples used for flow cytometry and FACS were acquired with a BD LSR Fortessa or
BD Influx Cell Sorter (BD Biosciences), and the cell populations were analyzed using FlowJo
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software. All experiments included fluorescence-minus-one and single-stained controls and
were performed at MD Anderson’s South Campus Flow Cytometry & Cell Sorting Core Facility.

Western blots. Cells were washed with a 10% fetal bovine serum (FBS)/phosphate-buffered
saline (PBS) solution (FBS/PBS) and pellets were resuspended in Mammalian Cell & Tissue
Extraction Kit buffer (BioVision Incorporated, Milpitas, CA) and incubated for 15 minutes with
gentle shaking. Lysates were then collected after centrifugation for 20 minutes at 12,000 rpm
and 4°C. The amount of protein was quantified using the Qubit™ Protein Assay Kit and a Qubit
fluorometer (both from Thermo Fisher Scientific). Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and Western blotting were performed following standard protocols. Blotted
membranes were incubated with primary monoclonal antibodies against human BCL2 (clone
124, Dako), MCL1 (Cell Signaling Technology, Danvers, MA), and vinculin (clone hVIN-1,
Sigma-Aldrich) and with secondary anti-mouse and anti-rabbit digital antibodies (Kindle
Biosciences LLP, Durham, NC). Membranes were developed using the SuperSignal™ West
Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific) in a KwikQuant Imager
(Kindle Biosciences LLP).

Immune cell staining. BM MNC pellets were washed with PBS and incubated with Zombie
UV™ Fixable Viability dye (BioLegend, San Diego, CA) in PBS for 15 minutes at room
temperature (RT) and in the dark. After incubation, cells were washed with thawing buffer (50%
FBS, 25% NaCl solution, and 25% anticoagulant solution) and were stained with 11 antibodies
against surface markers as described below, for 40 minutes at 4°C and in the dark. After
staining, cells were washed with thawing buffer and incubated with 1x Fix solution from the
TruNuclear Transcription Factor Buffer Set (BioLegend) for 1 hour at 4°C in the dark. When the
incubation was finished, cells were washed three times with 1x permeabilization buffer and
stained with an intracellular antibody against FOXP3 as described below, for 45 minutes at RT
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and in the dark. After the intracellular staining, cells were washed with permeabilization buffer
and then with thawing buffer. They were then resuspended in 350 µL of 2% FBS/PBS and
transferred to flow cytometry tubes for cytometric analysis as described below.

Patient-derived xenograft mouse models. Mice were maintained under specific-pathogenfree conditions at MD Anderson mouse facility. All animal experiments were performed with the
approval of MD Anderson’s Institutional Animal Care and Use Committee. All animal studies
used 5-week-old mice unless otherwise indicated. NSGS (NSG-SGM3) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). NSG-SGM3 mice were sub-lethally irradiated
and were injected with 0.5x106 patient-derived CD3- BM MNCs. Engraftment was periodically
assessed by determining the human CD45 chimerism rate by flow cytometric analysis of BM
aspirates as described above. If chimerism analysis indicated that there was significant
engraftment of human cells, mice were randomized into four groups: control, ABT-199, AMG176, and their combination. For ABT-199 treatment, mice were treated with 50mg/kg/day of
ABT-199 daily by oral gavage for two weeks and/or with 30 mg/kg/day of AMG-176 treatment
on the first two days of the week for two weeks. At the end of the treatment, the mice were
sacrificed and autopsied, and their rear legs were resected for analysis. For BM flow cytometric
analyses, femurs and tibias were crushed in the presence of a 2% FBS/PBS solution, the cell
suspensions were passed through 30 µm pre-separation filters (Miltenyi Biotec), and the cells
were counted to assess BM cellularity. BM cells were stained with fluorochrome-conjugated
antibodies as described below.

Drugs and treatments. ABT-199 was provided by AbbVie (North Chicago, IL). For in vitro
experiments, ABT-199 was dissolved in DMSO and diluted in PBS. For in vivo experiments,
fresh suspensions of ABT-199 in a 60:30:10 mix of Phosal 50 PG (Lipoid, Newark, NJ),
polyethylene glycol (PEG) 400, and ethanol were prepared weekly and stored at +4°C. ABT23

199 was administered by gavage at a dose of 50 mg/kg/day. AMG-176 was provided by Amgen
(Thousand Oaks, CA). For in vitro experiments, AMG-176 was dissolved in DMSO and diluted
in PBS. For in vivo experiments, fresh suspensions of AMG-176 in 25% hydroxypropyl beta
cyclodextrin with NaOH were sonicated for 2 hours at 60°C (pH=9), which were prepared
weekly and stored at RT. Mice were given 30 mg/kg daily on the first two days of the week for
two weeks by oral gavage.

Histological analyses. All human BM biopsy specimens (core biopsy specimens) were
routinely collected and processed in MD Anderson’s Department of Hematopathology. BM
biopsy specimens were fixed in 10% neutral buffered formaldehyde, and core biopsy
specimens were further decalcified using 10% formic acid for 3 h at 50°C in a microwave
processor. Specimens were embedded in paraffin, and 4 μm sections were prepared for
antibody detection. Immunohistochemistry (IHC) was performed at the Dana Farber/Harvard
Cancer Center Specialized Histopathology Core (Boston, MA). Formalin-fixed paraffinembedded samples were stained with anti-human BCL2 (clone 124; Dako, Agilent, Santa
Clara, CA) and counterstained with hematoxylin.

scRNA-seq. For scRNA-seq, BM samples were first processed and enriched as described
above, and 3,000 Lin-CD34+ cells were sorted by FACS. Sample preparation and sequencing
were performed at MD Anderson’s Sequencing and Microarray Facility. Sample concentration
and cell suspension viability were evaluated using a Countess II FL Automated Cell Counter
(Thermo Fisher Scientific) and manual counting. Samples were normalized for input onto the
Chromium Single Cell A Chip Kit (10x Genomics, Pleasanton, CA), in which single cells were
lysed and barcoded for reverse-transcription. The pooled single-stranded, barcoded cDNA was
amplified and fragmented for library preparation. During library preparation, appropriate
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sequence primer sites and adapters were added for sequencing on a NextSeq 500 sequencer
(Illumina).
After sequencing, fastq files were generated using the cellranger mkfastq pipeline
(version 3.0.2). The raw reads were mapped to the human reference genome (refdatacellranger-GRCh38-3.0.0) using the cellranger count pipeline. The digital expression matrix
was extracted from the filtered_feature_bc_matrix folder outputted by the cellranger count
pipeline. Multiple samples were aggregated using the cellranger aggr pipeline. The digital
expression matrix was analyzed with the R package Seurat (version 3.0.2) [70] to identify
different cell types and signature genes for each. Cells with fewer than 500 unique molecular
identifiers or greater than 50% mitochondrial expression were removed from further analysis.
The Seurat function NormalizeData was used to normalize the raw counts. Variable genes
were identified using the FindVariableFeatures function. The ScaleData function was used to
scale and center expression values in the dataset, and the number of unique molecular
identifiers was regressed against each gene. PCA, tSNE, and uniform manifold approximation
and projection (UMAP) were used to reduce the dimensions of the data, and the first two
dimensions were used in the plots. The FindClusters function was used to cluster the cells.
Marker genes for each cluster were identified using the FindAllMarkers function. Cell types
were annotated based on the marker genes and their match to canonical markers.

CyTOF analysis. The CyTOF panel was modified from the AML panel that Dr. Andreeff
established previously to include MDS HSPC markers. Briefly, sequential samples will be
stained with a CyTOF panel that includes 52 antibodies against lineage markers (e.g., CD45,
CD11b, CD4, CD8a, CD3, CD68, CD56, CD123, CD34, CD45RA, CD38, CD19, CD33, CD90,
HLA-DR, and HLA-ABC), BCL2 family proteins (i.e., BCL2, MCL1, PUMA, NOXA, BIM, BCL-XL,
BAD, and BAX), and proteins involved in signaling pathways (e.g., p-p65, p-4EBP1, p-STAT5,
p-GSK, p-STAT3, pS6, p-ERK, p-MEK1/2, p-AKT, and p-FLT3). To minimize variability in
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antibody staining and instrument sensitivity, the Cell-ID 20-Plex Pd barcoding kit was used.
This kit is ideal for barcoding clinical trial samples collected longitudinally and enables batched
samples collected at different times to be run simultaneously (up to 20 per run) [71]. ViSNE [72]
was used to analyze patients’ longitudinal data, which enabled us to characterize the BM cell
populations within each sample, track the way in which the composition of these populations
shifts before and after drug treatment, and identify the characteristics of vulnerable and drugresistant populations.
AML Panel 1
Isotope Antigen
89 CD45
102 CD45
103 CD45
104 CD45
105 CD45
106 CD45
108 CD45
110 CD45 (All
CD45 for
barcoding)
111 CD11B
112 CLA
113 CD8a
114 CD47
115 CD3
116 Cleaved
PARP
127 IDU
139 CD36
140 Ubiq
141 BCL-XL

AML Panel 2
Isotope Antigen
89 CD45
102 CD45
103 CD45
104 CD45
105 CD45
106 CD45
108 CD45
110 CD45
111
112
113
114
115
116
127
139
140
141

142 CD68

142

143
144
145
146

143
144
145
146

CD56
BCL2
CD123
BIM

CD11B
CLA
CD8a
CD47
CD3
Cleaved
PARP
IDU
CD36
Ubiq
pRb(S807/S
811)
cleaved
caspase
CD56
p-Tyrosine
CD123
BIM BD

AML Panel 3
Isotope Antigen
89 CD45
102 CD45
103 CD45
104 CD45
105 CD45
106 CD45
108 CD45
110 CD45

T- CELL
Isotope Antigen
89 CD45
102 CD45
103 CD45
104 CD45
105 CD45
106 CD45
108 CD45
110 CD45

111
112
113
114
115
116

CD45
CD45
CD8a
CD45
CD3
h2AX

111
112
113
114
115
116

127
139
140
141

IDU
CD7
CD14
PTEN

127
139
140
141

CD45
CLA
CD8
CD47
CD3
Cleaved
PARP
IDU
CD36
CD14
ccr6

142 CD68

142 CD27

143
144
145
146

143
144
145
146

VDAC1
GOT2
CD71
CD64

CD56
CD26
NKG2A
CD49F
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147 p4EBP1(T3
7/46)
148 CD34
149 BAD
150 pStat5(Y694
)
151 CLL-1
152 pStat3(Y705
)
153 P21
154 Ki-67
155 PDL1
156 CD38
157 CD19
158 CD33
159 p-AKT
160 Ythdf2

147 b-catenin

147 beta
catenin

147 CD127

148 CD34
149 p-NFKB
150 SOD2

148 CD34
149 CD99
150 CD304

148 CCR2
149 CCR4
150 CD28

151 CLL-1
152 A1, Bfl-1

151 HES1
152 CD86

151 TBET
152 TIGIT

153
154
155
156

153
154
155
156

CD45RA
CD13
HIF1A
Pp38(180/1
82)
157 CD19
158 CD33
159 CD135

153
154
155
156

160 PD-1

162
163
164
165
166

EOMES
CD137
CTLA4
CD25
LAG3

167
168
169
170
171
172
173
174
175
176
194
195

CXCR5
CD160
CD69
CD39
CD161
KLRG1
CD95
GITR
CD4
CD38
CD57
HLA ABC

BRD4
Ki-67
PDL1
CD38

157 CD19
158 CD33
159 pMAPKAPK
-2
160 p27

161 p-GSK-3
161Dy
162 Survivin
163 C-myc
164 MDM2
165 P53
166 c-kit

161 nrf2

160 ApoE
160Gd
161 CytoC

162
163
164
165
166

CDT1
c-myc
p-AMPK
p-creb
C-kit

162
163
164
165
166

167
168
169
170
171
172
173
174
175
176
194
195

167
168
169
170
171
172
173
174
175
176
194
195

p-ERK
MCT1
clpP
ARC
CD4
pS6
p-nrf2
bcl2
cxcr4
Cyclin B1
CD15
HLA ABC

167
168
169
170
171
172
173
174
175
176
194
195

p-ERK
NOXA
p-MEK1/2
Puma
CD4
pS6
Bax
p-FLT3
CXCR4
Mcl-1
CD15
HLA ABC

CD120B
Galectin-9
CD96
ABCB1
active Bcatenin
CD275
Mct1
p-ENOS
IdH1
Bax
hnrpk
CD70
CD200
p-FAK
IRF4
CD15
CD66

CD45RA
Ki-67
CCR7
TIM3

157 CD19
158 2B4
159 ICOS

161 CXCR3

27

196 Live dead

196 Live dead

196 LD

198 HLA-DR
209 H3K27

198 HLA-DR
209 IKBa

198 CD4
209 CD47

196 Live
Dead
198 HLA-DR
209 CD11b

Table 3. List of antibodies used for CyTOF analysis panel for BM MNCs from MDS
patients.
Data analysis. Flow cytometry data and cell culture data were analyzed with Prism 8 software
(GraphPad, La Jolla, CA). Figure legends indicate the statistical tests used in each experiment.
For the analyses involving human samples, investigators were blinded to sample annotations
and patient outcomes. Statistical significance was represented as *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001.

28

CHAPTER 4: RESULTS

29

4.1 “CMP pattern” MDS Patients Can Achieve More Favorable Outcomes in Response to
the Venetoclax-Based Therapy than “GMP Pattern” MDS Patients
To evaluate whether the immunophenotypic profile of MDS patients was associated
with the clinical outcomes of venetoclax-based therapy, we analyzed the frequencies of HSPCs
in total MNCs isolated from sequential BM samples of MDS patients enrolled in prospective
venetoclax-based clinical trials. Preliminary clinical data showed that patients with “GMP
pattern” MDS have a higher rate of disease progression without prior response than those with
the “CMP pattern” MDS do (Figure 4a). These results suggested that the “CMP pattern” MDS
patients could potentially achieve more favorable outcomes in response to the venetoclaxbased therapy. However, these data were preliminary because most of the patients included in
the analysis had received only a few cycles of therapy at the time of this Thesis submission.
Moreover, flow cytometry analysis of HSPCs in sequential samples showed that LT-HSCs were
depleted in the BM of “CMP pattern” MDS patients who responded to venetoclax-based
therapy (Figure 4b), which is consistent with our lab’s previous finding that BCL2 inhibition by
venetoclax could selectively eradicate disease-driving HSCs in patients with “CMP pattern”
MDS. In contrast, LMPPs from “GMP pattern” MDS patients were not significantly affected
during clinical responses (Figure 4b), suggesting that in “GMP pattern” MDS, the diseasedriving stem cells did not rely on BCL2-mediated anti-apoptotic mechanisms for survival and
disease propagation.
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Figure 4. Clinical outcomes of “CMP pattern” and “GMP pattern” MDS patients in
response to venetoclax-based therapy.
(a) Frequencies of complete remission (CR), complete remission with incomplete hematologic
recovery (CRi), marrow complete remission (mCR), stable disease (SD), and progressive
disease (PD) among 25 patients who received at least two cycles of venetoclax-based therapy
(P=0.07 for PD between the 2 MDS groups; chi-square test). (b) Frequencies of LT-HSCs in
the BM mononuclear cells (MNCs) of “CMP pattern” MDS patients at different times following
venetoclax based therapy (P=0.19 between cycle 0 [C0] of venetoclax-based therapy after
HMA therapy failure) and mCR; Wilcoxon matched pairs signed rank test. Only paired samples
were analyzed). (c) Frequencies of LMPPs in the BM MNCs of “GMP pattern” MDS patients at
different times after venetoclax based therapy.
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4.2 Single-cell RNA Sequencing (scRNA-seq) Analyses Revealed the Potential
Mechanisms of Venetoclax Resistance and Response in MDS Patients

4.2.1 Results from a representative “CMP pattern” MDS patient (P1)
To identify the potential molecular determinants of venetoclax response and resistance,
we analyzed the transcriptomic changes induced by venetoclax-based therapy in BM HSPCs
and MNCs isolated from sequential BM samples of two representative patients at the single-cell
level. Figure 5 shows the HSPC analysis of one of the patients with “CMP pattern” MDS (P1)
with ringed sideroblasts and TP53 and U2AF2 mutations. This patient was enrolled in the
clinical trial after HMA failure (Cycle 0 = C0). At time point C1, when the patient received one
cycle of venetoclax-based therapy and achieved marrow complete remission (mCR), the
proportion of HSC (Lin-CD34+CD38-) cells in BM MNCs as well as the frequency of LT-HSCs
(Lin-CD34+CD38-CD90+CD45RA-) in the HSC compartment decreased compared to that at
time point C0. However, the patient failed to respond to the second cycle of the therapy (C2)
and entered a pre-relapse stage followed by disease progression at C3 (BM sample not
available). Consistent with the clinical outcome, flow cytometry analysis showed that the BM
frequency of the HSC compartment dramatically increased at C2 (Figure 5).
ScRNA-seq analysis of HSPCs isolated from the same sequential BM samples revealed
that these cells underwent significant transcriptomic changes after the first cycle of venetoclaxbased therapy (C1) when this patient achieved mCR compared with the time of enrollment (C0)
(Figure 6a, b). Surprisingly, most HSPCs expressed MCL1 but not BCL2 (Figure 6c, d).
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Figure 5. Flow cytometry plots of HSPCs in BM MNCs isolated from a representative
“CMP pattern” MDS patient with TP53 and U2AF2 mutations
Patient P1 was enrolled in the clinical trial of venetoclax-based therapy after HMA therapy
failure (C0). The patient had marrow complete remission (mCR) after the first cycle of therapy
(C1) but had progression to AML after the second cycle (C2). Red squares indicate the LinCD34+CD38- population.
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Figure 6. Single-cell RNA sequencing (scRNA-seq) analysis in Lin-CD34+ HSPCs isolated
from sequential BM samples of a representative “CMP pattern” MDS patient
(a, b) Uniform manifold approximation and projection (UMAP) plots of single Lin-CD34+ HSPCs
isolated from a patient with “CMP pattern” MDS at three different times after venetoclax based
therapy and analyzed by scRNA-seq. Each dot represents one cell. The sample origin (a) and
the cluster identity (b) of each cell are indicated by different colors. (c, d) Violin plots of BCL2
(c) and MCL1 expression (d) in the three samples.

ScRNA-seq analysis of total BM MNCs isolated from this patient (Figure 7a, b)
revealed that, at C0 BCL2 was only expressed in CD4+ T cells (Figure 7c) but not in the
erythroid blasts. In addition, after the patient completed the first cycle of therapy and achieved
mCR, CD4+ T cells were enriched within the T and NK cell compartments (Figure 7d).
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Furthermore, the transcriptomic profile of the enriched CD4+ T cells suggested that they were
naïve and/or early-activated antigen-experienced cells with expression of CCR7, CD28, and
CD27 (Figure 7e). Pathway enrichment analysis of genes differentially expressed in CD4+ T
cells after venetoclax therapy compared with pre-treatment cells showed that venetoclax
significantly upregulated genes involved in the oxidative phosphorylation pathway and the
cytokine/inflammatory response (data not shown).
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Figure 7. Single-cell RNA (scRNA-seq) sequencing analysis in BM MNCs isolated from
the sequential BM samples of a representative “CMP pattern” MDS patient (P1)
(a, b) UMAPs of scRNA-seq data of single BM MNCs isolated from a patient with “CMP
pattern” MDS at three different times during venetoclax-based therapy. Each dot represents
one cell. Different colors indicate the sample origin (a) and the cluster identity (b) of each cell.
(c) Violin plot of BCL2 expression across the 13 MNC clusters. (d) Frequencies of CD4+ and
CD8+ lymphocytes and natural killer (NK) cells in the T and NK compartments at different times
of venetoclax-based therapy. HSPC, hematopoietic stem and progenitor cell; ERY, erythroid;
NK, natural killer. (e) UMAP plots of CCR7, CD27, and CD28 expressions among BM MNC
clusters.

Together, these results suggest that the initial response to venetoclax-based therapy in
this TP53-mutant patient was not mediated by targeting the HSPC and leukemic populations. It
is therefore tempting to hypothesize that the initial response to therapy was mediated by an
enhanced adaptive immune response. Of note, our immunohistochemistry analyses of BCL2
expression in the blasts of BM biopsies from 2 MDS patients carrying TP53 mutations after
HMA therapy failure and 2 MDS patients with wild-type TP53 (Figure 8), confirmed that BCL2
expression and TP53 mutations can be mutually exclusive in MDS.
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Figure 8. BCL2 expression and TP53 mutations are mutually exclusive.
BM biopsy specimens from 4 representative “CMP pattern” MDS patients with wild-type or
mutant TP53 and progressive disease, stained with anti-human BCL2 antibody.
UPIN#216: TP53 wild type with 5-10% CD34+ blasts; UPIN#042: TP53 wild type with 6%
CD34+ blasts; UPIN#121: TP53 mutant with 15% CD34+ blasts; UPIN#050: TP53 mutant with
41% CD34+ blasts, and 1% eosinophils which are positive for BCL2 staining regardless of the
genetic background and here are considered false positives. Magnification is 400x.

4.2.2 Results from a representative “GMP pattern” MDS patient (P2).
Next, we analyzed by scRNA-seq sequential samples from a representative “GMP
pattern” MDS patient (P2) with prior therapy failure and gene mutations in ASXL1, TET2,
RUNX1, and SRSF2. Flow cytometry analyses of HSPCs in sequential BM samples from this
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patient at five different times of therapy are shown in Figure 9: C0 (enrollment to the clinical
trial after prior therapy failure), C2, C4, C7, and C8. Notably, the initial diagnosis of this patient
was chronic myelomonocytic leukemia. When this patient relapsed after C8, the blastic cells
were LMPPs instead of monoblasts and they represented the 17.6% of BM MNCs compared
with the 0.26% at C0 (Figure 9). This is consistent with our previous findings that disease
progression in “GMP pattern” MDS is driven by the expansion of LMPPs.
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Figure 9. Flow cytometry plots of HSPCs in BM MNCs isolated from sequential BM
samples from a representative “GMP pattern” MDS patient (P2).
Patient P2 was enrolled in the clinical trial of venetoclax-based therapy after HMA therapy
failure (C0). The patient had marrow complete remission (mCR) after the second cycle of
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therapy (C2), stable disease (SD) after the fourth cycle (C4), and mCR after the seventh cycle
(C7), but had progression to AML (progressive disease, PD) after the eighth cycle (C8). The
red squares indicate the Lin-CD34+CD38- HSCs (first column) and LMPP populations (second
column); numbers by the red squares represent the frequencies of HSCs in the Lin-CD34+
HSPC compartment (first column) and the frequencies of LMPPs in the Lin-CD34+CD38- HSC
compartment.

The transcriptomic profile of BM MNCs isolated from patient P2’s sequential BM
samples analyzed by scRNA-seq (Figure 10a, b) also showed that neither the monoblasts nor
the LMPPs expressed BCL2, while MCL1 was highly expressed in both (Figure 10c, d),
suggesting that the direct cellular targets of venetoclax were not monoblasts or disease-driving
LMPPs. Since MCL1 can be upregulated by NF-B [64] and pathway enrichment analysis of
LMPPs isolated from P2 at C8 (progressive disease, PD) demonstrated that the genes involved
in the TNFα-induced NF-B signaling pathway were overexpressed in LMPPs after venetoclaxtherapy failure (Figure 10e), the high expression of MCL1 in P2’s HSPCs might be due to the
upregulation of the NF-B signaling pathway in LMPPs. This is consistent with our lab’s
previous finding that LMPPs of “GMP pattern” MDS patients with HMA failure are addicted to
the NF-B-mediated signaling pathway for survival. Together with our finding that MCL1, but
not BCL2, is upregulated in HSCs from “CMP pattern” patients with TP53 mutations (Figure 6,
7 and 8), these results suggest that targeting MCL1 may overcome venetoclax-based therapy
resistance.
Similar to the observation in the “CMP Pattern” MDS patient analyzed by scRNA-seq
(Figure 8c), BCL2 was highly expressed in T cells (Figure 10c) and T cell population
frequency changes also occurred when the patient achieved mCR during the venetoclax-based
treatment. CD4+ T cells with a naïve and/or early-activated antigen-experienced phenotype
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were enriched within the T and NK cell compartments when this patient underwent mCR
(Figure 10f).

41

Figure 10. Single-cell RNA (scRNA-seq) sequencing analysis in BM MNCs isolated from
the sequential BM samples from a representative “GMP pattern” MDS patient (P2).
(a, b) UMAP of scRNA-seq data of single BM MNCs cells isolated from a patient with “GMP
pattern” MDS (P2) at five different times during venetoclax-based therapy. Each dot represents
one cell. Different colors indicate the sample origin (a) and cluster identity (b) of each cell. (c,
d) Violin plots of BCL2 expression (c) and MCL1 expression (d) across the 15 MNC clusters.
HSPC, hematopoietic stem and progenitor cell; LMPP, lymphoid primed progenitors; ERY,
erythroid; MONO, monocytic; LYMPHO, lymphoid; NK, natural killer. (e) Pathways significantly
overexpressed in LMPPs at the time of disease progression after venetoclax-based therapy
failure. (f) UMAP plots of CCR7, CD27, and CD28 distributed among BM MNCs.

4.3 Mass Cytometry Analysis (CyTOF) Validated the Results of scRNA-seq Analysis at
Protein Level

4.3.1 Results from a representative “CMP pattern” MDS patient (P3).
To investigate whether the outcomes of venetoclax-based therapy were associated with
differential protein expression of critical anti-apoptotic BCL2 family proteins and to validate the
findings obtained using scRNA-seq analysis, we employed CyTOF to analyze MNCs isolated
from sequential BM samples from three additional MDS patients (P2, P3, and P4). Figure 11
illustrates the CyTOF analysis results of 4 sequential BM MNC samples from a representative
“CMP pattern” MDS patient with HMA failure and no TP53 mutations (P3). The patient
achieved mCR after C3 of venetoclax-based therapy but discontinued the therapy for reasons
not related to the response and developed progressive disease. Unlike the MDS patient with
TP53 mutation shown in the previous section (Figure 8), this patient had high protein
expression of BCL2 in the CD34+ HSPCs (Figure 11a-c). This results further confirmed our
lab’s previous finding that “CMP pattern” MDS patients without TP53 mutations acquire
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upregulation of BCL2 expression in the disease-driving HSCs following HMA failure. The fact
that the frequency of BCL2-expressing CD34+ HSPCs decreased before and at the time of
marrow response to therapy (Figure 11d) also supports our hypothesis that BCL2 inhibition by
venetoclax can selectively eradicate the disease-driving HSCs in “CMP pattern” MDS patients
with HMA failure.
Additionally, as shown in Figure 11d, CD4+ T cells were also enriched in the BM MNCs
when the patient responded to venetoclax-based therapy.

4.3.2 Results from representative “GMP pattern” MDS patients (P2, P4).
We next analyzed sequential samples from two representative “GMP pattern” MDS
patients by CyTOF (Figures 12 and 13).
CyTOF analysis results of BM MNCs isolated from P2 (analyzed by scRNA-seq in
section 4.2.2) were consistent with the scRNA-seq analysis results. MCL1, but not BCL2, was
highly expressed in the disease-driving LMPPs; and BCL2 was highly expressed in the T cell
populations (Figure 12a-c). Additionally, a subgroup of CD4+ T cells expanded when P2
achieved mCR (Figure 12d).
P4 achieved mCR after C2 and C4 of venetoclax-based therapy and progressed to AML
at C5. The Lin-CD34+ HSPCs of P4 expressed high levels of MCL1 but not BCL2 (Figure 13a
and b). Along with a dramatic expansion of the LMPP population at C5 (PD) (Figure 13c),
these results consistently validate our lab’s previous findings that LMPPs depend on NF-B
signaling pathways for survival in order to drive disease progression in “GMP pattern” MDS.
Likewise, BCL2 was highly expressed in T cells (Figure 13b and c) and a CD4+ T cell
population expanded when the patient responded to venetoclax-based therapy, indicating that
the response to venetoclax-based therapy in “GMP pattern” MDS patients could be mediated
by T cells instead of being the result of venetoclax-mediated direct targeting of HSCs.
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Figure 11. Cytometry by time of flight (CyTOF) analysis of BM MNCs isolated from
sequential BM samples from a representative “CMP pattern” MDS patient (P3).
(a) Visualization of t-distributed stochastic neighbor embedding (viSNE) plot of MNCs cells from
4 sequential samples isolated from a “CMP pattern” MDS patient after HMA failure. (b)
Heatmap of protein expression among the cell clusters at different time points during
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venetoclax-based therapy. (c) viSNE plots of MNCs from the 4 sequential samples showing the
expression of the BCL2 family proteins BCL2, MCL1, BCL-XL. (d) Dot plots showing the cell
cluster size at each therapy time point (SD, stable disease; C2, cycle 2 of venetoclax-based
therapy; C3, cycle 3 of venetoclax-based therapy; mCR, marrow complete remission; PD,
progressive disease)
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Figure 12. Cytometry by time of flight (CyTOF) analysis in BM MNCs isolated from
sequential BM samples of a representative “GMP pattern” MDS patient (P2).
(a) viSNE plot of MNCs cells from 4 sequential samples isolated from a “GMP pattern” MDS
patient (P2). (b) Heatmap of protein expression among the cell clusters at different time points
during venetoclax-based-therapy. (c) viSNE plots of MNCs from the 4 sequential samples
showing the expression of the BCL2 family proteins BCL2, MCL1, BCL-XL. (d) Dot plots
showing the cell cluster size at each therapy time point (mCR, marrow complete remission; C2,
cycle 2 of venetoclax-based therapy; SD, stable disease; C4, cycle 4 of venetoclax-based
therapy; PD, progressive disease; C8, cycle 8 of venetoclax-based therapy).
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Figure 13. Cytometry by time of flight (CyTOF) analysis in BM MNCs isolated from the
sequential BM samples from a representative “GMP pattern” MDS patient (P4).
(a) viSNE plot of MNCs cells from 4 sequential samples isolated from a “GMP pattern” MDS
patient. (b) viSNE plots of MNCs from the 4 sequential samples showing the expression of the
BCL2 family proteins BCL2, MCL1, and BCL-XL. (c) Dot plots showing the cell cluster size at
each therapy time point (mCR, marrow complete remission; C2, cycle 2 of venetoclax-based
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therapy; C4, cycle 4 of venetoclax-based therapy; PD, progressive disease; C5, cycle 5 of
venetoclax-based therapy).

4.4. T Cell Analyses by Flow Cytometry
Preliminary results of scRNA-seq and CyTOF analyses in sequential BM samples
isolated from MDS patients enrolled in venetoclax-based clinical trials revealed that a subtype
of CD4+ T cells expanded when patients achieved mCR. Therefore, we performed T cell
analysis by flow cytometry to identify the specific population that significantly changed during
response to venetoclax-based therapy. We analyzed BM MNCs isolated from sequential BM
samples obtained from 10 MDS patients enrolled in the clinical trials and quantified the
frequencies of the NK and T cell populations at different therapy times in correlation with the
type of clinical response. Specifically, we analyzed NK CD16hi, NK CD16lo, CD4+ T cells, CD8+
T cells, naïve T cells (TN), stem cell memory T cells (TSCM), terminal effector T cells (TE),
effector memory T cells (TEM), central memory T cells (TCM), regulatory T cells (Treg), and
CD45RO+CD45RA+ T cells based on their surface and intracellular markers (Table 2). We did
not observe any significant change in the frequencies of total CD4+ T cells, CD8+ T cells, and
NK cells in the BM MNCs over the course of the disease (Figure 14). However, our further
analysis of the specific sub-populations inside the CD4+, CD8+, and NK compartments revealed
that the CD4+ TSCM significantly expanded in the BM of patients who achieved mCR (Figure
15). Similar data were obtained when we analyzed the CD4+ TSCM frequency inside the CD4+ T
cell compartment (Figure 16), as well as when we performed paired analysis of these cells in
sequential samples (Figure 17). Interestingly, our paired analyses also showed that the CD4+
naïve T cell (TN) population increased when patients had mCR (Figure 17). These findings are
consistent with the results obtained by our scRNA-seq and CyTOF analyses showing that CD4+
T cell populations with a naïve and/or early-activated antigen-experienced phenotype, such as
TN and TSCM, expanded in the BM of patients who achieved mCR.
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Consistent with our previous data, we did not observe any significant change in the
CD8+ T cell subpopulations within either BM MNCs (Figure 18) or total CD8+ T cells (Figure
19) during venetoclax-based treatment.

Figure 14. T and NK cell quantification by flow cytometry.
Frequencies of (a) NK – natural killer cells, (b) NK cells with high surface expression of CD16,
(c) NK cells with low surface expression of CD16, (d) T cells, (e) CD4+ T cells, and (f) CD8+ T
cells in total BM MNCs from MDS patients (n=10). Samples were collected when patients were
enrolled into the clinical trials (C0) and during venetoclax-based therapy, at the times of stable
disease (SD), marrow complete remission (mCR), and progressive disease (PD). Data are
presented as means ± SEMs.
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Figure 15. CD4+ T cell quantification in BM MNCs by flow cytometry.
Frequencies of (a) CD4+ naïve T cells, (b) CD4+ stem cell memory T cell (SCM), (c) CD4+
terminal effector cells (TE), (d) CD4+ central memory T cells (CM), (e) CD4+ effector memory T
cells (EM), (f) CD4+CD45RO+CD45RA+ T cells, and (g) regulatory T cells (Treg) from MDS
patients (n=10) in total BM MNCs. Samples were collected when patients were enrolled into the
clinical trials (C0) and during venetoclax-based therapy, at the times of stable disease (SD),
marrow complete remission (mCR), and progressive disease (PD). Data are presented as
means ± SEMs.
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Figure 16. CD4+ T cell quantification in the CD4+ T cell compartment by flow cytometry.
Frequencies of (a) CD4+ naïve T cells, (b) CD4+ stem cell memory T cell (SCM), (c) CD4+
terminal effector T cells (TE), (d) CD4+ central memory T cells (CM), (e) CD4+ effector memory
T cells (EM), (f) CD4+CD45RO+CD45RA+ T cells, and (g) regulatory T cells (Treg) in total CD4+T
cells from MDS patients (n=10). Samples were collected when patients were enrolled into the
clinical trials (C0) and during venetoclax-based therapy, at the times of stable disease (SD),
marrow complete remission (mCR), and progressive disease (PD). Data are presented as
means ± SEMs.
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Figure 17. CD4+ T cell quantification in sequential patient samples by flow cytometry
Frequencies of (a) CD4+ naïve T cells, (b) CD4+ stem cell memory T cell (SCM). Cell number %
in total T CD4+ cells of (c) CD4+ naïve T cells, (d) CD4+ stem cell memory T cell (SCM) in total
BM MNCs from MDS patients (n=10). Samples were collected when patients were enrolled into
the clinical trials (C0) and during venetoclax-based therapy, at the times of stable disease (SD),
marrow complete remission (mCR), and progressive disease (PD). Only paired samples were
analyzed, and data are presented as means ± SEMs.
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Figure 18. CD8+ T cell quantification in BM MNCS by flow cytometry.
Frequencies of (a) CD8+ naïve T cells, (b) CD8+ stem cell memory T cell (SCM), (c) CD8+
terminal effector T cells (TE), (d) CD8+ central memory T cells (CM), (e) CD8+ effector memory
T cells (EM), (f) CD8+CD45RO+CD45RA+ T cells in total BM MNCs from MDS patients (n=10).
Samples were collected when patients were enrolled in the clinical trials (C0) and during
venetoclax-based therapy, at the times of stable disease (SD), marrow complete remission
(mCR), and progressive disease (PD). Data are presented as means ± SEMs.
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Figure 19. CD8+ T cell quantification in the CD8+ compartment by flow cytometry.
Frequencies of (a) CD8+ naïve T cells, (b) CD8+ stem cell memory T cell (SCM), (c) CD8+
terminal effector T cells (TE), (d) CD8+ central memory T cells (CM), (e) CD8+ effector memory
T cells (EM), (f) CD8+CD45RO+CD45RA+ T cells in CD8+ compartment from MDS patients
(n=10). Samples were collected when they were enrolled in the clinical trials (C0) and during
venetoclax-based therapy, at the times of stable disease (SD), marrow complete remission
(mCR), and progressive disease (PD). Data are presented as means ± SEMs.
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4.5 Assessing the Feasibility of Targeting MCL1 in Venetoclax-Resistant MDS

4.5.1 The combination of venetoclax and AMG-176 can synergistically eradicate MDS-L
cells in vitro.
Results from our scRNA-seq and CyTOF analyses suggested that MCL1, but not BCL2,
is highly expressed in both HSPCs and blasts from “GMP pattern” MDS. We, therefore,
hypothesized that MCL1 inhibition could effectively target MDS stem cells in BCL2-negative,
thus venetoclax-resistant MDS. To test the hypothesis, we performed pre-clinical studies using
the MCL1 inhibitor AMG-176. First, we treated the MDS-L cell line, the only available cell line in
MDS research, with venetoclax and AMG-176 as single agents or in combination. The MDS-L
line was established from a patient with MDS at the time of disease progression [73] and
expresses both BCL2 and MCL1 (Figure 20a). We observed that MDS-L cells were highly
resistant to 48-hour single-agent treatments with either venetoclax (IC50 ≈1 µM) or AMG-176
(IC50 > 10 µM) (Figure 20b-e). However, the combination of venetoclax (200 nM) and AMG176 (200 nM, 500 nM) could significantly induce apoptosis in MDS-L cells, as shown by
Annexin V/DAPI analysis by flow cytometry (Figure 21a, b). Taken together, these results
suggested that BCL2 inhibition by venetoclax and MCL1 inhibition by AMG-176 could
synergistically eradicate venetoclax-resistant MDS-L cells.
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Figure 20. Effect of single-agent treatments with venetoclax (ABT-199) and AMG-176 on
MDS-L cells.
(a) Western blot showing MCL1 and BCL2 expression in MDS-L cells. Vinculin was used as
loading control. HL-60 and JJN3 cells were used as positive controls. (b, c) Effect of ABT-199
treatment on MDS-L (b) cell number and (c) cell viability. MDS-L cells were treated in vitro with
vehicle (DMSO) or increasing concentrations of ABT-199 for the indicated time points. (d, e)
The effect of AMG-176 treatment on MDS-L (d) cell number and (e) cell viability. MDS-L cells
were treated in vitro with vehicle (DMSO) or increasing concentrations of AMG-176 for 48
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hours. Data were normalized to the vehicle-treated controls and are presented as means ±
SEMs.

Figure 21. Apoptosis analysis and quantification in MDS-L cells after treatment with
venetoclax (ABT-199) and AMG-176, as single agents and in combination.
(a) Representative flow cytometry plots of apoptosis analysis by Annexin V/DAPI staining in
MDS-L cells treated with vehicle (DMSO) and 200 nM of ABT-199 alone or in combination with
200 or 500 nM of AMG-176 in vitro for 48 hours. (b) Frequency of MDS-L cells that underwent
apoptosis after being treated with 200 nM of ABT-199 and 200 nM or 500 nM of ABT-176 as
single agents or in combination for 48 hours in vitro. Data are presented as means ± SEMs.
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4.5.2 The combination of venetoclax and AMG-176 can synergistically suppress MDS
stem cell survival in vitro.
Next, we sought to evaluate whether AMG-176 as a single agent or in combination with
venetoclax could eradicate venetoclax-resistant MDS stem cells. We isolated Lin-CD34+
HSPCs from MDS patients, co-cultured them with human mesenchymal stromal cells (MSCs)
isolated from healthy donors and treated the co-cultures with venetoclax and AMG-176 as
single agents or in combinations at a safe dose that spared normal HSPCs for 48 hours
(Figure 22a, b). Harvested cells were quantified by flow cytometry. We observed that in “CMP
pattern” MDS the Lin-CD34+CD38- HSCs were sensitive to venetoclax as a single agent
(Figure 22c), which supported our previous finding that BCL2 inhibition by venetoclax could
selectively eradicate the disease-driving stem cells in “CMP pattern” MDS. In addition, singleagent treatment with AMG-176 at 50 nM also significantly decreased the number of diseasedriving stem cells, the effect of which was further enhanced by combining AMG-176 with
venetoclax (Figure 22d). In contrast, the Lin-CD34+CD38- HSCs from “GMP pattern” MDS
patients were not sensitive to the single-agent treatments with venetoclax or AMG-176 but
responded to the combination treatment. Altogether, these results demonstrate the therapeutic
potential of MCL1 inhibition by AMG-176 in combination with venetoclax to effectively eradicate
venetoclax-resistant MDS blasts and disease-driving HSCs in vitro.
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Figure 22. Effect of single-agent and combination treatments with venetoclax (ABT-199)
and AMG-176 in primary MDS HSCs.
(a) Diagram representing the co-culture system of MDS CD34+ HSPCs with healthy human
MSCs. Cells were treated with venetoclax (ABT-199) and AMG-176 as single agents or in
combination for 48 hours, followed by flow cytometry analysis. (b) Dose-response curves
showing the numbers of live CD34+CD38- HSCs, long-term hematopoietic stem cells (LTHSCs), multipotent progenitors (MPPs), and lymphoid-primed multipotent progenitors (LMPPs)
from the BM of healthy donors after 48 h of treatment with increasing doses of AMG-176. Data
were normalized to the vehicle-treated controls and are presented as means ± SEMs (n=3
samples). (c, d) Numbers of live CD34+CD38- cells from samples of “CMP pattern” MDS (n=2)
(c) or “GMP pattern” MDS (n=9) (d) at disease progression after treatment with vehicle or
AMG-176 at the indicated doses in the presence or absence of 20 nM venetoclax (ABT-199).
Data were normalized to the vehicle-treated controls and are presented as means ± SEMs.
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4.5.3 The combination of venetoclax and AMG-176 can significantly decrease BM
chimerism in a “GMP pattern” MDS patient-derived xenograft (PDX).
To investigate whether AMG-176 as a single agent or in combination with venetoclax
could effectively reduce venetoclax-resistant tumor burden in vivo, we established a PDX
model of venetoclax-resistant MDS by transplanting T cell-depleted BM MNCs isolated from a
“GMP pattern” MDS patient into NSG-SGM3 mice (Figure 23a). Based on our previous
findings, cells from this patient were predicted to be resistant to treatment with venetoclax.
Indeed, the blasts from this “GMP pattern” MDS PDX model were resistant to venetoclax and
AMG-176 as single agents following two weeks of treatment, but they were sensitive to the
combination of both agents, as indicated by the significant decrease in the chimerism of human
CD45+ cells in the BM (Figure 23b). These results suggest that the combination of venetoclax
and AMG-176 can overcome venetoclax resistance in vivo.
We had also transplanted T cell-depleted BM MNCs isolated from a venetoclaxresistant “CMP pattern” MDS patient into NSG-SGM3 mice. Unfortunately, due to the nonengraftment of these cells into the mice after 12 weeks, we could not start the treatments. This
was not due to our technical deficiency, but it was the result of the intrinsic inability of MDS
cells to reconstitute hematopoiesis in recipient mice.
Of note, our studies also highlight that the PDX models possibly fail to faithfully
recapitulate and mimic complex diseases, such as MDS, in which the adaptive immune
response plays a fundamental role in achieving disease remission after therapy.
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Figure 23. Effect of single-agent and combination treatments with venetoclax (ABT-199)
and AMG-176 on a representative “GMP pattern” MDS patient-derived xenograft model
(PDX).
(a) Schematic image of the PDX experiment. NSG-SGM3 mice (n=22) were sub-lethally
irradiated and injected with 0.5x106 patient-derived T cell-depleted (CD3-) MNCs. Mice were
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treated with 50 mg/kg/day of ABT-199 daily by oral gavage for two weeks and/or with 30
mg/kg/day AMG-176 on the first two days of the week for two weeks. At the endpoint,
chimerism was assessed in the BM by flow cytometry. (b) Frequencies of human CD45+ cells
in BM cells from xenografts developed from a representative “GMP pattern” MDS sample after
treatment with vehicle, AMG-176, ABT-199, or the combination of both agents (AMG+ABT).
Bars represent the means ± SEMs.
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CHAPTER 5: DISCUSSION
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Previous studies that involved high-throughput next-generation sequencing techniques
demonstrated that MDS are maintained and propagated by HSCs with cumulative somatic
mutations [74]. Our lab revealed that two different immunophenotypically distinct hierarchical
cellular organizations of MDS HSPCs contribute to therapy resistance and disease progression
by the upregulation of specific survival pathways. As explained in the introduction section of
this Thesis, MDS patients can be stratified into two subtypes based on their immunophenotypic
hierarchies: “CMP pattern” and “GMP pattern” MDS. “CMP pattern” MDS were characterized by
having an increased frequency of the CMPs among MyHPCs and an expansion of the LTHSCs driven by BCL2-mediated anti-apoptotic mechanisms following HMA failure. “GMP
pattern” MDS were defined by having an increased frequency of the GMPs among the
MyHPCs and an expansion of the LMPPs driven by NF-B-mediated survival pathways
following HMA failure. Our preclinical results demonstrated that the inhibition of the survival
pathways driving each MDS subgroup’s progressive disease could selectively eradicate the
respective MDS stem cells and decrease tumor burden in PDX models.
In our study, we employed the BCL2 inhibitor venetoclax (ABT-199). Clinical trials of
venetoclax-based therapy for MDS patients who have failed previous therapies are ongoing at
MD Anderson Cancer Center, allowing us to validate our preclinical findings through correlative
studies. Indeed, the preliminary data presented in this study support the hypothesis that
targeting BCL2 with venetoclax can elicit a durable response in “CMP pattern” MDS. As more
eligible MDS patients are recruited, we expect to update the results with a larger sample cohort
to validate this conclusion.
The development of novel therapeutics should include the identification of potential
mechanisms of response and resistance in order to appropriately design clinical studies and
potentially include precise and effective combination therapies. Therefore, we sought to identify
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biomarkers of venetoclax response and resistance in MDS by employing scRNA-seq and
CyTOF to analyze sequential BM samples from MDS patients enrolled in prospective clinical
trials of venetoclax for the treatment of HMA-resistant MDS. Our scRNA-seq and IHC data
showed that BCL2 was not expressed in neither the HSPCs nor the blasts from BM of “CMP
pattern” MDS patients with a TP53 mutation or “GMP pattern” MDS patients. However, T cells
from both types of MDS subgroups expressed BCL2 and underwent significant population
changes, indicating that the initial response to venetoclax therapy was not due to the direct
targeting of either disease-driving HSPCs or blast populations but it was the results of the
adaptive T cell response.
Throughout various clinical studies, it has been demonstrated that TP53 mutations in
cancer patients were correlated with poor clinical outcomes and poor prognosis with
venetoclax-based therapy [75]. Furthermore, loss of function of TP53 can confer cancer cell
resistance to BCL2 inhibition by perturbing gene expression of pro-apoptotic BCL2 family
proteins and decreasing the level of BCL2 expression [75]. Together with the IHC BCL2
quantification in BM biopsies from TP53-mutated MDS, our study suggests that TP53
mutations and BCL2 expression are mutually exclusive. These data also suggest that TP53mutant MDS patients should be treated with specific inhibitors of mutant TP53, such as APR246 [76].
In addition, our data show that MCL1 was expressed in the majority of blasts and
HSPCs of the TP53-mutated “CMP pattern” MDS patient and was highly expressed in LMPPs
of all “GMP pattern” MDS patients. Because MCL1 is one of the downstream transcriptional
targets of NF-B [64], these results are consistent with our previous study showing that LMPPs
of “GMP pattern” MDS patients rely on the upregulation of the NF-B survival pathway to
maintain and propagate the disease. These results also suggest that MCL1 expression may be

65

one of the mechanisms that account for venetoclax resistance in MDS, leading to our
hypothesis that MCL1 inhibition can effectively target leukemogenic stem cells in venetoclaxresistant MDS. Our preclinical results demonstrate that MCL1 inhibition by the small-molecule
BH3 mimetic AMG-176 in combination with venetoclax can eradicate MDS blasts and stem
cells in vitro and reduce venetoclax-resistant tumor burden in vivo. Altogether, our study
substantiates the feasibility of targeting MCL1 by AMG-176 to overcome venetoclax resistance
in MDS. Recently, a phase I/II clinical trial to evaluate the safety and activity of AMG-176-based
therapy in MDS patients who have failed prior therapy and developed progressive disease has
been initiated at MD Anderson Cancer Center (MDACC 2021-0276). Future correlative studies
using samples from patient enrolled in this clinical trial will assess the efficacy of AMG-176based therapy in targeting MDS HSCs.
Apart from the response or resistance of MDS blasts and HSPCs to venetoclax therapy,
we observed changes in the frequencies of the CD4+ T cell populations during venetoclaxbased treatment, which suggests a role of the adaptive immune system in venetoclax
response. ScRNA-seq analysis revealed that a subset of naïve and/or early-activated antigenexperienced CD4+T cells with expression of CCR7, CD28, and CD27 was enriched only when
MDS patients achieved mCR. Based on the hierarchical model of T cell differentiation, naïve T
cells (TN) undergo rapid proliferation and differentiation upon antigen recognition. They can
generate effector T cells (TE) for immediate immune response to eradicate pathogens or
differentiate into long-lived memory T cells that respond to recurrent antigens and maintain
long-term immune surveillance [77]. The memory T cell subsets include effector memory T
cells (TEM), central memory T cells (TCM), and stem cell memory T cells (TSCM) [60]. Our T cell
analysis results showed a significant increase in populations of CD4+TN and TSCM in the bone
marrow of MDS patients at the time when they responded to venetoclax-based therapy,
suggesting enhanced TN activation during the response. The rise of TSCM, therefore, might be a
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consequence of rapid TN differentiation. Our results suggest that, when MDS patients respond
to venetoclax-based therapy, their naïve T cells undergo rapid proliferation and differentiation,
preferentially to TSCM, which may be one potential mechanism that induces favorable outcomes
to venetoclax treatment. However, the factors that contribute to TN activation and whether this
is induced directly by venetoclax remain unknown. Previous studies demonstrated that TN could
be stimulated by antigen presentation and cytokine secretion of dendritic cells or by proinflammatory cytokines in an antigen-independent manner [78]. Reduced effectiveness of
antigen presentation resulting from an immunosuppressive tumor microenvironment (TME) can
lead to insufficient T cell activation and exertion of an anti-tumor response [79]. Thus, it is
possible that the increased proliferation of TN was due to enhanced and prolonged antigen
presentation induced by venetoclax treatment.

TSCM is a rare subset of long-lasting memory T cells that possess the ability of selfrenewal and exhibit effector functions, including TNF-α, interferon-gamma (IFN-γ), and
interleukin-2 (IL-2) secretion [59]. They were first described by Gattinoni et al. in 2011 as a
subset of memory T cells that maintained stem cell-like properties, had increased proliferation
capacity and efficiency of reconstitution, and displayed enhanced anti-tumor activity in a
humanized mouse model compared with naïve and other memory T cell subsets [80] . Later,
studies have shown that TSCM plays an essential role in directing anti-tumor response and
maintaining long-term immune surveillance in various types of cancers [59]. These properties
make TSCM a great candidate for adoptive immunotherapy [81]. Thus, in our case, the increase
in the TSCM population upon response to venetoclax-based therapy might indicate an enhanced
anti-tumor activity against leukemic cells mediated by T cells. However, the mechanisms by
which the increased TSCM in BM potentially contribute to leukemic cell eliminations need to be
further investigated. Since TSCM possesses a superior ability to self-renew and differentiate into
downstream memory and effector cells to exert rapid immune response [80], the elevation of
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TSCM in venetoclax responders might consequently generate a more significant number of
differentiated and activated memory and effector cells. Indeed, our data suggested that when
MDS patients achieved mCR, they had an increase in transition from naïve/stem cell memory T
cells to effector/central memory T cells. Therefore, upon the recurrent stimulation of a potential
leukemic cell antigen, the effectiveness and efficiency of memory T cell activation in venetoclax
responders may be more profound than in the non-responders. To understand whether the
memory T cell subsets are clonal and can recognize antigens that are specific for leukemic
cells, single-cell T cell receptor sequencing (scTCR-seq) can be performed to evaluate the
specificity of T cell receptor repertoires [82].

In addition, the reasons why non-responders failed to elevate TSCM population are
unknown. One possible explanation is T cell exhaustion, one of the T cell dysfunctions
characterized by decreased cytokine secretion and poor effector function [83]. Thus, it would
be interesting to evaluate the T cell profile by scRNA-sequencing for the expression of T cell
exhaustion markers [84] and investigate the polyfunctionality of T cells in venetoclax
responders and non-responders, which can be assessed by performing single-cell cytokine
profiling [85].

In conclusion, our T cell analysis data suggest that venetoclax response is associated
with the expansion of CD4+TN and TSCM. Therefore, future studies should be directed toward
understanding the dynamics of T cell differentiation and activation when interacting with the
TME and the polyfunctionality of T cells in MDS patients who respond or are refractory to
venetoclax-based therapy.
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